Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE study of COVID-19 vaccination response in autoimmune rheumatic and inflammatory bowel disease
ACTRN12621000661875Phase 4Completed
- Sponsor
- Dr Ai Tran
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tozinameran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Dr Ai Tran. Primary endpoints: Antibody response to Pfizer-BioNTech vaccine and Antibody response to Oxford-AstraZeneca vaccine. Started May 2021; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621000661875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000661875.